India Meningococcal Vaccines Market

ID: MRFR/Pharma/51390-HCR
200 Pages
Vikita Thakur
Last Updated: February 06, 2026
India Meningococcal Vaccines Market Research Report: Size, Share, Trend Analysis By Vaccine Type (Monovalent Vaccines, Multivalent Vaccines, Conjugate Vaccines), By Age Group (Infants, Children, Adolescents, Adults), By Administration Route (Intramuscular, Subcutaneous, Oral) and By Distribution Channel (Hospitals, Clinics, Pharmacies Forecast to 2035
India Meningococcal Vaccines Market
Market Size
Forecast Period2025 - 2035
CAGR (2025 - 2035)3.48%
2024 Market Size$ 229.5 Million
2025 Market Size$ 238.3 Million
2035 Market Size$ 334.5 Million
Key Players
Serum Institute of India
Bharat Biotech
Zydus Cadila
Biological E. Limited
Sanofi Pasteur
GlaxoSmithKline
Trends
  • Rising Awareness and Education
  • Government Initiatives and Support
  • Innovations in Vaccine Development
Opportunities
  • Public Awareness Campaigns
  • Rising Healthcare Expenditure
  • Government Vaccination Programs
Summary Table of Contents Segmentation Download PDF
  1. 1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
    1. 1.1 EXECUTIVE SUMMARY
      1. 1.1.1 Market Overview
      2. 1.1.2 Key Findings
      3. 1.1.3 Market Segmentation
      4. 1.1.4 Competitive Landscape
      5. 1.1.5 Challenges and Opportunities
      6. 1.1.6 Future Outlook
  2. 2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
    1. 2.1 MARKET INTRODUCTION
      1. 2.1.1 Definition
      2. 2.1.2 Scope of the study
        1. 2.1.2.1 Research Objective
        2. 2.1.2.2 Assumption
        3. 2.1.2.3 Limitations
    2. 2.2 RESEARCH METHODOLOGY
      1. 2.2.1 Overview
      2. 2.2.2 Data Mining
      3. 2.2.3 Secondary Research
      4. 2.2.4 Primary Research
        1. 2.2.4.1 Primary Interviews and Information Gathering Process
        2. 2.2.4.2 Breakdown of Primary Respondents
      5. 2.2.5 Forecasting Model
      6. 2.2.6 Market Size Estimation
        1. 2.2.6.1 Bottom-Up Approach
        2. 2.2.6.2 Top-Down Approach
      7. 2.2.7 Data Triangulation
      8. 2.2.8 Validation
  3. 3 SECTION III: QUALITATIVE ANALYSIS
    1. 3.1 MARKET DYNAMICS
      1. 3.1.1 Overview
      2. 3.1.2 Drivers
      3. 3.1.3 Restraints
      4. 3.1.4 Opportunities
    2. 3.2 MARKET FACTOR ANALYSIS
      1. 3.2.1 Value chain Analysis
      2. 3.2.2 Porter's Five Forces Analysis
        1. 3.2.2.1 Bargaining Power of Suppliers
        2. 3.2.2.2 Bargaining Power of Buyers
        3. 3.2.2.3 Threat of New Entrants
        4. 3.2.2.4 Threat of Substitutes
        5. 3.2.2.5 Intensity of Rivalry
      3. 3.2.3 COVID-19 Impact Analysis
        1. 3.2.3.1 Market Impact Analysis
        2. 3.2.3.2 Regional Impact
        3. 3.2.3.3 Opportunity and Threat Analysis
  4. 4 SECTION IV: QUANTITATIVE ANALYSIS
    1. 4.1 Healthcare, BY Application (USD Million)
      1. 4.1.1 Vaccination Programs
      2. 4.1.2 Travel Health
      3. 4.1.3 Outbreak Response
      4. 4.1.4 Routine Immunization
      5. 4.1.5 Special Population Immunization
    2. 4.2 Healthcare, BY End Use (USD Million)
      1. 4.2.1 Government Healthcare Facilities
      2. 4.2.2 Private Healthcare Facilities
      3. 4.2.3 Pharmaceutical Distributors
      4. 4.2.4 Non-Governmental Organizations
    3. 4.3 Healthcare, BY Age Group (USD Million)
      1. 4.3.1 Infants
      2. 4.3.2 Children
      3. 4.3.3 Adolescents
      4. 4.3.4 Adults
    4. 4.4 Healthcare, BY Vaccine Type (USD Million)
      1. 4.4.1 Conjugate Vaccines
      2. 4.4.2 Polysaccharide Vaccines
      3. 4.4.3 Recombinant Vaccines
  5. 5 SECTION V: COMPETITIVE ANALYSIS
    1. 5.1 Competitive Landscape
      1. 5.1.1 Overview
      2. 5.1.2 Competitive Analysis
      3. 5.1.3 Market share Analysis
      4. 5.1.4 Major Growth Strategy in the Healthcare
      5. 5.1.5 Competitive Benchmarking
      6. 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare
      7. 5.1.7 Key developments and growth strategies
        1. 5.1.7.1 New Product Launch/Service Deployment
        2. 5.1.7.2 Merger & Acquisitions
        3. 5.1.7.3 Joint Ventures
      8. 5.1.8 Major Players Financial Matrix
        1. 5.1.8.1 Sales and Operating Income
        2. 5.1.8.2 Major Players R&D Expenditure. 2023
    2. 5.2 Company Profiles
      1. 5.2.1 Serum Institute of India (IN)
        1. 5.2.1.1 Financial Overview
        2. 5.2.1.2 Products Offered
        3. 5.2.1.3 Key Developments
        4. 5.2.1.4 SWOT Analysis
        5. 5.2.1.5 Key Strategies
      2. 5.2.2 Bharat Biotech (IN)
        1. 5.2.2.1 Financial Overview
        2. 5.2.2.2 Products Offered
        3. 5.2.2.3 Key Developments
        4. 5.2.2.4 SWOT Analysis
        5. 5.2.2.5 Key Strategies
      3. 5.2.3 Zydus Cadila (IN)
        1. 5.2.3.1 Financial Overview
        2. 5.2.3.2 Products Offered
        3. 5.2.3.3 Key Developments
        4. 5.2.3.4 SWOT Analysis
        5. 5.2.3.5 Key Strategies
      4. 5.2.4 Biological E. Limited (IN)
        1. 5.2.4.1 Financial Overview
        2. 5.2.4.2 Products Offered
        3. 5.2.4.3 Key Developments
        4. 5.2.4.4 SWOT Analysis
        5. 5.2.4.5 Key Strategies
      5. 5.2.5 Sanofi Pasteur (FR)
        1. 5.2.5.1 Financial Overview
        2. 5.2.5.2 Products Offered
        3. 5.2.5.3 Key Developments
        4. 5.2.5.4 SWOT Analysis
        5. 5.2.5.5 Key Strategies
      6. 5.2.6 GlaxoSmithKline (GB)
        1. 5.2.6.1 Financial Overview
        2. 5.2.6.2 Products Offered
        3. 5.2.6.3 Key Developments
        4. 5.2.6.4 SWOT Analysis
        5. 5.2.6.5 Key Strategies
      7. 5.2.7 Merck & Co. (US)
        1. 5.2.7.1 Financial Overview
        2. 5.2.7.2 Products Offered
        3. 5.2.7.3 Key Developments
        4. 5.2.7.4 SWOT Analysis
        5. 5.2.7.5 Key Strategies
      8. 5.2.8 Pfizer (US)
        1. 5.2.8.1 Financial Overview
        2. 5.2.8.2 Products Offered
        3. 5.2.8.3 Key Developments
        4. 5.2.8.4 SWOT Analysis
        5. 5.2.8.5 Key Strategies
      9. 5.2.9 Novartis (CH)
        1. 5.2.9.1 Financial Overview
        2. 5.2.9.2 Products Offered
        3. 5.2.9.3 Key Developments
        4. 5.2.9.4 SWOT Analysis
        5. 5.2.9.5 Key Strategies
    3. 5.3 Appendix
      1. 5.3.1 References
      2. 5.3.2 Related Reports
  6. 6 LIST OF FIGURES
    1. 6.1 MARKET SYNOPSIS
    2. 6.2 INDIA MARKET ANALYSIS BY APPLICATION
    3. 6.3 INDIA MARKET ANALYSIS BY END USE
    4. 6.4 INDIA MARKET ANALYSIS BY AGE GROUP
    5. 6.5 INDIA MARKET ANALYSIS BY VACCINE TYPE
    6. 6.6 KEY BUYING CRITERIA OF HEALTHCARE
    7. 6.7 RESEARCH PROCESS OF MRFR
    8. 6.8 DRO ANALYSIS OF HEALTHCARE
    9. 6.9 DRIVERS IMPACT ANALYSIS: HEALTHCARE
    10. 6.10 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE
    11. 6.11 SUPPLY / VALUE CHAIN: HEALTHCARE
    12. 6.12 HEALTHCARE, BY APPLICATION, 2024 (% SHARE)
    13. 6.13 HEALTHCARE, BY APPLICATION, 2024 TO 2035 (USD Million)
    14. 6.14 HEALTHCARE, BY END USE, 2024 (% SHARE)
    15. 6.15 HEALTHCARE, BY END USE, 2024 TO 2035 (USD Million)
    16. 6.16 HEALTHCARE, BY AGE GROUP, 2024 (% SHARE)
    17. 6.17 HEALTHCARE, BY AGE GROUP, 2024 TO 2035 (USD Million)
    18. 6.18 HEALTHCARE, BY VACCINE TYPE, 2024 (% SHARE)
    19. 6.19 HEALTHCARE, BY VACCINE TYPE, 2024 TO 2035 (USD Million)
    20. 6.20 BENCHMARKING OF MAJOR COMPETITORS
  7. 7 LIST OF TABLES
    1. 7.1 LIST OF ASSUMPTIONS
  8. 7.1.1
    1. 7.2 India MARKET SIZE ESTIMATES; FORECAST
      1. 7.2.1 BY APPLICATION, 2026-2035 (USD Million)
      2. 7.2.2 BY END USE, 2026-2035 (USD Million)
      3. 7.2.3 BY AGE GROUP, 2026-2035 (USD Million)
      4. 7.2.4 BY VACCINE TYPE, 2026-2035 (USD Million)
    2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
  9. 7.3.1
    1. 7.4 ACQUISITION/PARTNERSHIP
  10. 7.4.1

India Meningococcal Vaccines Market Segmentation

India Meningococcal Vaccines Market By Application (USD Million, 2026-2035)

  • Vaccination Programs
  • Travel Health
  • Outbreak Response
  • Routine Immunization
  • Special Population Immunization

India Meningococcal Vaccines Market By End Use (USD Million, 2026-2035)

  • Government India Meningococcal Vaccines Market Facilities
  • Private India Meningococcal Vaccines Market Facilities
  • India Meningococcal Vaccines Market Distributors
  • Non-Governmental Organizations

India Meningococcal Vaccines Market By Age Group (USD Million, 2026-2035)

  • Infants
  • Children
  • Adolescents
  • Adults

India Meningococcal Vaccines Market By Vaccine Type (USD Million, 2026-2035)

  • Conjugate Vaccines
  • Polysaccharide Vaccines
  • Recombinant Vaccines

Related Reports

No regional reports available for this market.

No country-specific reports available for this market.

Customer Stories

Case Study Cover Image
Case Study

Aerospace & Defense

Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.